Shanghai Pharmaceuticals Holding Co., Ltd. (SPH; HKG: 2607, SHA: 601607) and Henlius (HKG: 2696) announced a strategic cooperation agreement to expand hospital market development and deepen international business collaboration, with focused engagement on innovative drug products. The partnership leverages Shanghai Pharma’s commercial platform and Henlius’s R&D innovation capabilities to enhance healthcare accessibility and accelerate global footprint expansion.
Partnership addresses “last mile” challenge of getting innovative biologics from approval to patient prescription
Revenue Synergy: Combined platform targets RMB 2+ billion incremental sales over 3 years through co-promotion and shared distribution
Pipeline Integration: Potential for priority access to Henlius pipeline assets for SPH; SPH early-stage innovative assets for Henlius development input
Forward‑Looking Statements This brief contains forward‑looking statements regarding partnership execution, hospital market penetration, and international expansion for the Shanghai Pharmaceuticals-Henlius collaboration. Actual results may differ due to competitive dynamics in hospital procurement, regulatory changes affecting innovative drug pricing, and geopolitical factors affecting international business development.-Fineline Info & Tech
By Fineline Cube 